米纳瑞斯制药 MLYS

Jon Congleton has served as our President and Chief Executive Officer and as a member of our board of directors since November 2020. Previously, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries Limited (Teva) from November 1996 to December 2014, where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.

Adam Levy has served as our Chief Financial Officer since March 2022 and as our Chief Business Officer from March 2022 through January 4, 2024. Mr. Levy also serves as a member of the board of directors of Praxis Bioresearch. Previously, he was the Chief Financial Officer at Sanifit Therapeutics until the company was acquired by Vifor Pharma in 2022. Previously, Adam served as the Chief Business Officer at Brickell Biotech from 2019 to 2020 and led the organization's financial operations transition as it became a publicly listed company on Nasdaq. Prior to that, he served as the Chief Business Officer at miRagen Therapeutics from 2016 to 2019, where he was responsible for a variety of functions including financial strategy, investor relations, business development, legal affairs, intellectual property, project and program management, and human resources. Between 2000 and 2016, Mr. Levy held multiple investment banking positions at Merrill Lynch, Jefferies Group, and Wedbush Securities. Mr. Levy received a B.S. in Business Management and Marketing from Cornell University.

Glenn P. Sblendorio has served as a member of our board of directors since September 2023. Most recently, Mr. Sblendorio was a member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company focused on the development and commercialization of therapeutics for progressive non-viral liver diseases, including its lead product Ocaliva for primary biliary cholangitis. Intercept Pharmaceuticals was acquired by Alfasigma in November 2023. He also served as Chief Executive Officer and a member of the board of directors of IVERIC bio, Inc., a publicly-held biotechnology company (formerly Ophthotech Corporation), from July 2017 until it was acquired by Astellas Pharma in July 2023. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March 2006 through March 2016 and was a member of the board of directors of The Medicines Company from July 2011 through December 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company specializing in the development and commercialization of anti-angiogenic therapies for serious ocular diseases, including neovascular age-related macular degeneration. Eyetech Pharmaceuticals was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also served as a Managing Director of MPM Capital Advisors from 1998 through 2000. Mr. Sblendorio serves as a member of the board of directors of Amicus Therapeutics, Inc. and of 4D Molecular Therapeutics, Inc. and Chairman of Nanoscope Therapeutics, Inc. Mr. Sblendorio also serves on the board of directors of RetiNova, a private biotech company focused on treatments for retinal diseases. Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University and is a graduate of the Harvard Advanced Management Program.

Daphne Karydas, M.B.A., has served on our board of directors since September 2023. Since February 2023, Ms. Karydas served as President and Chief Financial Officer, and since October 2021 as Chief Operating Officer and Chief Financial Officer, of Flare Therapeutics Inc., a pre-clinical pharmaceutical company. Prior to joining Flare, she served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from July 2020 to October 2021. Ms. Karydas previously served as Senior Vice President of Corporate Strategy and Financial Planning & Analysis at Allergan plc, where she oversaw the company's long-term financial and business strategy, until its acquisition by AbbVie Inc. in May 2020. She joined Allergan in April 2017 as Senior Vice President of Global Investor Relations and Strategy, leading engagement with the investment community and corporate strategy development. Prior to joining Allergan, she served as Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management from January 2015 to April 2017. Previously, she was a Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Earlier in her career, Ms. Karydas was a Vice President at Goldman Sachs Asset Management focused on healthcare, as well as a member of Goldman Sachs' healthcare investment banking team. Before joining Goldman Sachs, she was a Project Chemical Engineer at Merck & Co., Inc., where she focused on process development for novel vaccines. Ms. Karydas has served on the board of directors of COMPASS Pathways plc since September 2023, a publicly-traded, clinical-stage biotechnology company focused on developing psilocybin-based mental health treatments. She previously served on the board of directors of LogicBio Therapeutics, a publicly-traded, clinical-stage genetic medicine company, until its acquisition by Alexion Pharmaceuticals, Inc. in October 2022. In addition, she served on the board of directors of Eucrates Biomedical Acquisition Corp., a publicly-traded special purpose acquisition company formed to pursue business combinations in the biomedical and healthcare sectors, from May 2020 to April 2023. Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

Alexander Gold, M.D. has served on our board of directors since June 2024. Dr. Gold also has served as the Chief Medical Officer of Beren Therapeutics, a clinical-stage biotech company, since August 2023. Prior to his current role, he was Head Medical Officer at CSL Vifor, the nephrology and iron-deficiency therapeutic business of CSL Ltd. (CSL), from August 2022 until August 2023. Dr. Gold originally joined Sanifit, Inc. as Chief Medical Officer and President in November 2017. At that time, Sanifit, Inc. was then a private, clinical-stage biopharmaceutical company developing therapies for progressive vascular calcification disorders in patients with end-stage renal disease undergoing hemodialysis. Sanifit, Inc. was acquired by Vifor Pharma, a global pharmaceutical company focused on iron deficiency, nephrology, and cardio-renal therapies, in January 2022, and later became part of CSL, a publicly-traded, global biotechnology company with a broad portfolio of plasma-derived therapies, vaccines, gene therapies, and treatments across immunology, hematology, and nephrology, following CSL's acquisition of Vifor Pharma in August 2022. Prior to Sanifit, Inc., Dr. Gold held the role of Senior Vice President and Head of Clinical Development at Portola Pharmaceuticals from 2013 to 2017. Prior to Portola Pharmaceuticals, Dr. Gold was Head of Clinical Development at Reata Pharmaceuticals. Prior to Reata Pharmaceuticals and since 2001, he held multiple leadership positions at AstraZeneca, including the Executive Director and Development Leader for BRILINTA, CRESTOR, and ONGLYZA. Dr. Gold is currently an Adjunct Professor at the Stanford University School of Medicine. Dr. Gold received a B.A. from Brandeis University and an M.D. from Harvard Medical School.

Derek DiRocco, Ph.D. has served on our board of directors since May 2022. Dr. DiRocco has been a partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, since December 2020 and was previously a principal from December 2017 until December 2020, an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the board of directors of Evommune, Inc. since October 2024, and Acrivon Therapeutics, Inc. since November 2022, each of which is a publicly-traded biotechnology company. Dr. DiRocco previously served on the board of directors of publicly-traded clinical-stage biopharmaceutical companies Achilles Therapeutics plc, Connect Biopharma Holdings Limited, Werewolf Therapeutics, Inc. (from which he resigned effective at the company's 2025 annual meeting of stockholders), 89bio, Inc., and iTeos Therapeutics, Inc., and also serves on the board of directors of several privately held biotechnology companies. Dr. DiRocco holds a B.A. in biology from the College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women's Hospital/Harvard Medical School.

Srinivas Akkaraju, M.D., Ph.D. has served on our board of directors since February 2021. Dr. Akkaraju has served as Managing General Partner of Samsara BioCapital, a venture capital firm, since he founded the firm in 2017. From April 2013 to March 2017, Dr. Akkaraju was a General Partner and then a Senior Advisor of Sofinnova Ventures, a venture capital firm focused on the life sciences industry. From January 2009 until April 2013, Dr. Akkaraju was a Managing Director of New Leaf Venture Partners, an investment firm focused on the healthcare technology sector. From 2006 to 2008, Dr. Akkaraju served as a Managing Director of Panorama Capital, a venture capital firm that he co-founded along with other members of the former venture capital investment team of J.P. Morgan Partners, a private equity division of JPMorgan Chase & Co. Prior to co-founding Panorama Capital, Dr. Akkaraju was with JPMorgan Partners, which he joined in 2001 and of which he became a partner in 2005. From 1998 to 2001, Dr. Akkaraju worked in business and corporate development at Genentech, Inc. (now a member of the Roche Group), a biotechnology company. Dr. Akkaraju has been a director of publicly-traded biopharmaceutical companies Scholar Rock Holding Corporation since July 2022, Syros Pharmaceuticals, Inc. from June 2017 to February 2025, and Kalaris Therapeutics, Inc. since March 2025. Dr. Akkaraju also serves on the board of directors of vTv Therapeutics Inc., Alumis Inc., and Inventiva S.A., each of which is a publicly-traded, clinical-stage biopharmaceutical company with a therapeutic focus on chronic, immune-related, or metabolic diseases, well as a number of private companies. During the past five years, Dr. Akkaraju previously served as a director of the publicly-traded, clinical-stage biopharma companies Chinook Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Aravive, Inc. (formerly Versartis, Inc.), aTyr Pharma, Inc., Jiya Acquisition Corp., Principia Biopharma Inc., and Seattle Genetics, Inc. (now Seagen Inc.). Dr. Akkaraju received his M.D. and a Ph.D. in Immunology from Stanford University and holds undergraduate degrees in Biochemistry and Computer Science from Rice University.

Brian Taylor BT Slingsby, M.D., Ph.D., M.P.H. founded Mineralys in May 2019 and has served on our board of directors since that time and as Executive Chairman through December 31, 2024. Dr. Slingsby is Founder & Managing Director at Catalys Pacific, a venture capital firm focused on life sciences. Dr. Slingsby is a physician-scientist and biotechnology entrepreneur leading the company creation efforts for Catalys Pacific. He has served as founding CEO and subsequent executive chairman of Mineralys, Pathalys Pharma, Inc., Crystalys Therapeutics, Inc., Kirilys Therapeutics, Inc., Accelys Pharma, Inc., Aculys Pharma, Inc., Hepalys Pharma, Inc., and Renalys Pharma, Inc., each of which is an early- or clinical-stage biopharmaceutical company. Prior to Catalys Pacific, he founded and served as CEO and Executive Director of the Global Health Innovative Technology Fund - the world's first public-private fund focused on the development of new medicines for low- and middle-income countries. Previously, he was an executive at Eisai Co., Ltd. following his time in academia. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University. An author on over 50 peer-reviewed articles on medicine and public health, he formerly served as a Visiting Professor at Keio University, Kyoto University and Osaka University and Visiting Research Fellow at the University of Tokyo.

On August 5, 2026, the Company's Board of Directors appointed James J. Ferguson III, M.D., as the Company's new Chief Medical Officer, effective August 10, 2026. Terry brings more than 35 years of experience in cardiovascular medicine and drug development, including serving as Cardiovascular Therapeutic Area Head at Amgen, nearly a decade in cardiovascular leadership roles at AstraZeneca and The Medicines Company, as well as more than two decades on the faculty of the Texas Heart Institute. Most recently, he served as Chief Medical Officer at Cadrenal Therapeutics. In his new role, Terry will lead Mineralys' medical and late-stage clinical activities.

Eric Warren, R.Ph. has served as our Chief Commercial Officer since April 2025. Previously, Mr. Warren was at Esperion Therapeutics, Inc., a commercial-stage biopharmaceutical company, where he most recently served as its Chief Commercial Officer from March 2022 to April 2025, and previously in roles as Vice President, US Sales and Marketing from January 2021 to March 2022. From August 2020 to January 2021, Mr. Warren was Vice President, Head of Sales and Marketing at Nabriva Therapeutics plc, a commercial-stage biopharmaceutical company. From April 2018 to August 2020, Mr. Warren held Vice President roles in marketing at Sanofi S.A., a pharmaceutical and healthcare company, in their cardiovascular franchise. Additionally, from May 2006 to April 2018, Mr. Warren held roles of increasing responsibility at Merck & Co., a pharmaceutical company. Mr. Warren holds a Bachelor of Science in Pharmacy and is a licensed pharmacist in New York State.